Search - tctmd.com

Displaying 81 - 100 of 342

Sort: Relevancy | Date

Presentation TCT 2020

TCT 066: Ischemic and Bleeding Outcomes in Patients With vs. Without Atrial Fibrillation: Analysis From the Onyx ONE Month DAPT Program

Presenter: Sanjeevan Pasupati

October 14, 2020

Presentation TCT 2020

TCT 060: Contribution of ESC DAPT Guideline-Endorsed High Thrombotic Risk Features to Long-Term Clinical Outcomes Among Patients With and Without High Bleeding Risk After PCI

Presenter: Hao-Yu Wang

October 14, 2020

News Opinion Editor's Corner TCT 2020

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

Shelley Wood

October 09, 2020

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

Todd Neale

October 03, 2019

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Todd Neale

September 30, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

Presentation TCT 2019

Case 3: A Patient With AF and ACS

Presenter: C. Michael Gibson

September 28, 2019

Presentation TCT 2019

Case 2: A Patient With Complex Disease Who Requires Noncardiac Surgery

Presenter: Sunil Rao

September 28, 2019

Presentation TCT 2019

Case 1: A Complex Multivessel PCI in an Elderly Woman

Presenter: James Hermiller

September 28, 2019

Presentation TCT 2019

Approaches to Reduce Bleeding Risk Post PCI in Patients Requiring OAC: Is There Any Role for ASA?

Presenter: C. Michael Gibson

September 28, 2019

Presentation TCT 2019

Role of New-Gen DES in Patients at HBR: Does Stent Type Matter?

Presenter: Ajay Kirtane

September 28, 2019

Presentation TCT 2019

Welcome, Introductions, and Session Goals

Presenter: Roxana Mehran

September 28, 2019

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

Presentation TCT 2019

DAPT After PCI With DCB: Current Guidelines and Special Considerations

Presenter: Marco Valgimigli

September 28, 2019

Presentation TCT 2019

STOPDAPT-2 HBR: 1-Year Outcomes From a Randomized Trial of Clopidogrel Monotherapy vs. DAPT Beginning 1 Month After PCI in Patients at High Bleeding Risk

Presenter: Hirotoshi Watanabe

September 28, 2019

Presentation TCT 2019

The Science Behind Xience: From EXCEL to Short DAPT

Presenter: Sripal Bangalore

September 28, 2019

Presentation TCT 2019

The Evolving SYNERGY Programs: EVOLVE-Short DAPT Updates

Presenter: Ajay Kirtane

September 28, 2019

Presentation TCT 2019

GLOBAL LEADERS: Ticagrelor Monotherapy vs. DAPT After PCI in TWILIGHT-Like Patients

Presenter: Yoshinobu Onuma

September 27, 2019

Presentation TCT 2019

Regulatory Considerations for High Bleeding Risk Patients Undergoing PCI

Presenter: Adrian Magee

September 27, 2019

Presentation TCT 2019

Defining High Bleeding Risk: HBR ARC

Presenter: Philip Urban

September 27, 2019

Advertisement

TCT 066: Ischemic and Bleeding Outcomes in Patients With vs. Without Atrial Fibrillation: Analysis From the Onyx ONE Month DAPT Program

TCT 060: Contribution of ESC DAPT Guideline-Endorsed High Thrombotic Risk Features to Long-Term Clinical Outcomes Among Patients With and Without High Bleeding Risk After PCI

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Case 3: A Patient With AF and ACS

Case 2: A Patient With Complex Disease Who Requires Noncardiac Surgery

Case 1: A Complex Multivessel PCI in an Elderly Woman

Approaches to Reduce Bleeding Risk Post PCI in Patients Requiring OAC: Is There Any Role for ASA?

Role of New-Gen DES in Patients at HBR: Does Stent Type Matter?

Welcome, Introductions, and Session Goals

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

DAPT After PCI With DCB: Current Guidelines and Special Considerations

STOPDAPT-2 HBR: 1-Year Outcomes From a Randomized Trial of Clopidogrel Monotherapy vs. DAPT Beginning 1 Month After PCI in Patients at High Bleeding Risk

The Science Behind Xience: From EXCEL to Short DAPT

The Evolving SYNERGY Programs: EVOLVE-Short DAPT Updates

GLOBAL LEADERS: Ticagrelor Monotherapy vs. DAPT After PCI in TWILIGHT-Like Patients

Regulatory Considerations for High Bleeding Risk Patients Undergoing PCI

Defining High Bleeding Risk: HBR ARC

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content